MedTrace Logo

MxA-Guided Antiviral Treatment in Respiratory Viral Infections

NCT06668025 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2026-03-04

No results posted yet for this study

Summary

This pilot randomized controlled trial (RCT) will investigate the clinical impact of Myxovirus Resistance Protein A (MxA)-guided antiviral treatment versus standard treatment in patients with respiratory viral infections.

Conditions

  • Respiratory Viral Infections
  • Influenza
  • SARS CoV-2

Interventions

OTHER

MxA tests

Whole blood samples will be collected on Days 1, 4, 7, and 10 for MxA testing. MxA measurements on Days 4, 7, and 10 will be performed only for patients still hospitalized on antiviral thearpy or at the attending physician's discretion.

OTHER

MxA feedback

MxA results will be reported to the attending physician within 4 hours, along with MxA-based antiviral treatment guidelines.

OTHER

Follow-up at Day 30

A telephone visit will be conducted on or around Day 30 for study participants who are discharged, to collect information on antiviral usage, recurrence infection, readmissions, and additional medical visits.

Sponsors & Collaborators

  • China-Japan Friendship Hospital

    collaborator OTHER

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • Capital Medical University

    lead OTHER

Principal Investigators

  • Bin Cao · China-Japan Friendship Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-12
Primary Completion
2026-01-28
Completion
2026-02-12

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06668025 on ClinicalTrials.gov